Rani Therapeutics Holdings (RANI) Retained Earnings (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Retained Earnings of -$8000.0 for Q1 2026, down 500.0% year-over-year from $2000.0 in Q1 2025, and up 99.99% quarter-over-quarter from -$132.6 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Retained Earnings (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Retained Earnings history runs 7 years deep, the most recent figure standing at -$8000.0 for Q1 2026.
- In Q1 2026, Retained Earnings fell 500.0% year-over-year to -$8000.0; the TTM figure through Mar 2026 stood at -$8000.0 (down 500.0% YoY), while the FY2025 annual figure was -$132.6 million, down 226.4% from the prior year.
- Retained Earnings for Q1 2026 stood at -$8000.0, up from -$132.6 million in the prior quarter.
- The five-year high for Retained Earnings was $104.9 million in Q4 2024, with the low at -$132.6 million in Q4 2025.
- The 5-year median for Retained Earnings is -$8000.0 (2026), against an average of $8.7 million.
- Peak annual rise in Retained Earnings reached 236848.78% in 2024, while the deepest fall reached 138276.19% in 2024.
- Rani Therapeutics Holdings' Retained Earnings stood at $75.8 million in 2022, then grew by 13.08% to $85.8 million in 2023, then gained by 22.3% to $104.9 million in 2024, then tumbled by 226.4% to -$132.6 million in 2025, then surged by 99.99% to -$8000.0 in 2026.
- Business Quant data shows RANI's Retained Earnings at -$8000.0 in Q1 2026, -$132.6 million in Q4 2025, and $3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | 186.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 186.26 Mn |
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | -132.58 Mn |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 104.89 Mn |
| Sep 30, 2024 | 97.07 Mn |
| Jun 30, 2024 | -87.18 Mn |
| Mar 31, 2024 | 87.78 Mn |
| Dec 31, 2023 | 85.76 Mn |
| Sep 30, 2023 | -41,000.00 |
| Jun 30, 2023 | -63,000.00 |
| Mar 31, 2023 | -47.30 Mn |
| Dec 31, 2022 | 75.84 Mn |
| Sep 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -22.18 Mn |
| Mar 31, 2022 | -14.60 Mn |
| Dec 31, 2021 | -8.33 Mn |
| Sep 30, 2021 | 54.50 Mn |